Anthropometric Correlates of Insulin-Like Growth Factor 1 (IGF-1) and IGF Binding Protein-3 (IGFBP-3) Levels by Race/Ethnicity and Gender

Cancer Prevention Fellowship Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Annals of epidemiology (Impact Factor: 2). 12/2009; 19(12):841-9. DOI: 10.1016/j.annepidem.2009.08.005
Source: PubMed


Insulin-like growth factor 1 (IGF-1) levels are positively related to some cancers and negatively related to cardiovascular disease. These conditions are also related to insulin resistance and high body weight, leading to the hypothesis that IGF-1 levels may, in part, mediate the association of high body weight with these health outcomes. Using the National Health and Nutrition Examination Survey (NHANES) III population, we examined the associations between IGF-1, IGF binding protein-3 (IGFBP-3), and the IGF-1/IGFBP-3 molar ratio with anthropometric measures in a large, U.S. population-based study where these associations could also be stratified by race/ethnicity and gender.
The study population consisted of 3,168 women and 2,635 men (44% non-Hispanic white, 28.2% non-Hispanic black, and 27.7% Mexican-American). Anthropometric measures were obtained by trained personnel in the NHANES mobile examination centers. IGF-1 and IGFBP-3 were measured using immunoassays by staff at Diagnostic System Laboratories (DSL) Inc. (Webster, TX). Associations of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio with anthropometric variables across race/ethnicity and gender were evaluated by using linear regression modeling.
Body mass index (BMI) was inversely associated with IGF-1 levels across all of the race/ethnicity and gender subgroups. In contrast, BMI, waist to hip ratio (WHR), and waist circumference were positively associated with IGFBP-3 levels only in non-Hispanic black men and non-Hispanic white women. The IGF-1/IGFBP-3 molar ratio was inversely associated with all anthropometric measures, except height, in all subgroups of the population.
The significant inverse associations of BMI with IGF-1 levels and of all anthropometric variables, except height, with the IGF-1:IGFBP-3 molar ratio in all subgroups do not support existing hypotheses that associations of excess weight with negative health outcomes, such as specific cancer diagnoses, are mediated through high IGF-1 levels.

Download full-text


Available from: Nancy Potischman, Oct 07, 2015
24 Reads
  • Source
    • "There is evidence for deregulation of the growth hormone/insulin-like growth factor (IGF-1) signaling in obesity [13,14] and an inverse relationship between total IGF-1 levels and BMI has been reported [15,16]. In FM patients we have recently reported a beneficial role of IGF-1 and exercise with regard to pain [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Severe fatigue is a major health problem in fibromyalgia (FM). Obesity is common in FM, but the influence of adipokines and growth factors is not clear. The aim was to examine effects of exercise on fatigue, in lean, overweight and obese FM patients. In a longitudinal study, 48 FM patients (median 52 years) exercised for 15 weeks. Nine patients were lean (body mass index, BMI 18.5 to 24.9), 26 overweight (BMI 25 to 29.9) and 13 obese. Fatigue was rated on a 0 to 100 mm scale (fibromyalgia impact questionnaire [FIQ] fatigue) and multidimensional fatigue inventory (MFI-20) general fatigue (MFIGF). Higher levels in FIQ fatigue and MFIGF indicate greater degree of fatigue. Free and total IGF-1, neuropeptides, adipokines were determined in serum and cerebrospinal fluid (CSF). Baseline FIQ fatigue correlated negatively with serum leptin (r = -0.345; P = 0.016) and nerve growth factor (NGF; r = -0.412; P = 0.037). In lean patients, baseline MFIGF associated negatively with serum resistin (r = -0.694; P = 0.038). FIQ Fatigue associated negatively with CSF resistin (r = -0.365; P = 0.073). Similarly, FIQ fatigue (r = -0.444; P = 0.026) and MFIGF correlated negatively with CSF adiponectin (r = -0.508; P = 0.01). In lean patients, FIQ fatigue (P = 0.046) decreased after 15 weeks. After 30 weeks, MFIGF decreased significantly in lean (MFIGF: P = 0.017), overweight (MFIGF: P = 0.001), and obese patients (MFIGF: P = 0.016). After 15 weeks, total IGF-1 increased in lean (P = 0.043) patients. ∆Total IGF-1 differed significantly between lean and obese patients (P = 0.010). ∆Total IGF-1 related negatively with ∆MFIGF after 15 weeks (r = -0.329; P = 0.050). After 30 weeks, ∆FIQ fatigue negatively correlated with ∆NGF (r = -0.463; P = 0.034) and positively with ∆neuropeptide Y (NPY) (r = 0.469; P = 0.032). Resistin increased after 30 weeks (P = 0.034). ∆MFIGF correlated negatively with ∆resistin (r = -0.346; P = 0.031), being strongest in obese patients (r = -0.815; P = 0.007). In obese patients, ∆FIQ fatigue after 30 weeks correlated negatively with ∆free IGF-1 (r = -0.711; P = 0.032). Exercise reduced fatigue in all FM patients, this effect was achieved earlier in lean patients. Baseline levels of resistin in both serum and CSF associated negatively with fatigue. Resistin was increased after the exercise period which correlated with decreased fatigue. Changes in IGF-1 indicate similar long-term effects in obese patients. This study shows reduced fatigue after moderate exercise in FM and indicates the involvement of IGF-1 and resistin in these beneficial effects. Trial registration NCT00643006
    Arthritis research & therapy 02/2013; 15(1):R34. DOI:10.1186/ar4187 · 3.75 Impact Factor
  • Source
    • "There has also been a similar relation demonstrated in other large studies conducted in Western countries among men and women with a slightly lower average BMI than the participants in this study (Holmes et al. 2002; Lukanova et al. 2002; 2004) and in a previous analysis of a sub-group of the women in this study population (Gram et al. 2006). On the other hand, others have shown inverse (DeLellis et al. 2004; Irwin et al. 2005; Schernhammer et al. 2007; Faupel-Badger et al. 2009), positive (Probst-Hensch et al. 2001; Teramukai et al. 2002) and null associations (Goodman-Gruen and Barrett-Connor 1997; Ben-Shlomo et al. 2003; Probst-Hensch et al. 2003) between BMI and IGF-I. The most likely explanation for this discrepancy is the variation in BMI and the differences in the cut-points used to define the categories of BMI between the studies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Height and BMI are risk factors for several types of cancer and may be related to circulating concentrations of insulin-like growth factor-I (IGF-I), a peptide associated with increased cancer risk. To assess the associations between height, BMI and serum concentrations of IGF-I and IGF binding protein (IGFBP)-1, -2 and -3. This cross-sectional analysis included 1142 men and 3589 women aged 32-77 years from the multi-centre study, the European Prospective Investigation of Cancer and Nutrition (EPIC). In men, there was a positive association between height and IGF-I; each 10 cm increment in height was associated with an increase in IGF-I concentrations of 4.3% (95% confidence interval (CI): 1.3-7.5%, p for trend = 0.005), but this association was not statistically significant for women (0.9%, 95% CI: - 0.7 to 2.6%, p for trend = 0.264). In both men and women, the association between IGF-I and BMI was non-linear and those with a BMI of 26-27 kg/m² had the highest IGF-I concentration. BMI was strongly inversely related to concentrations of IGFBP-1 and IGFBP-2 in men and in women (p for trend for all < 0.001). Height and BMI are associated with IGF-I and its binding proteins, which may be mechanisms through which body size contributes to increased risk of several cancers.
    Annals of Human Biology 03/2011; 38(2):194-202. DOI:10.3109/03014460.2010.507221 · 1.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic syndrome (MetS), cardiovascular diseases(CVD) and cancers such as colon cancer (CCa), prostate cancer(PCa) and breast cancer (BCa) have been recognized asobesity-initiated diseases. The development of obesity cancause changes in metabolic and hormonal conditions, whichcan result in the storage of excess energy in different forms inthe human body. Existing anthropometric data are useful in theprognosis of these diseases. Although frequently studied, thereis disagreement on the applicability, reliability and trends ofweight, height, waist circumference (WC) and relevant indices.WC is generally accepted as a key marker in CVD and CCarisk assessment whereas more evidence of the usefulness ofWC-CVD, WC-PCa and WC-BCa correlations is needed. Thebody mass index, which has been widely used as a determinantof obesity, has a strong connection with CCa risk in men andyoung women, but an inconsistent connection with BCa. Cross-referencing measurements,with indices such as the waist-to-height ratio (WHtR) and waist-to-hip ratio (WHR),enhances the association with diseases, e.g. WHtR-CVD and WHR-CCa, and connectionsare strong. This idea is further applied to multiple referencing. For example, theWHtR/WHR has been studied and found highly correlated with the MetS risk in Asia. Inaddition, latent issues (such as tools or techniques for surface anthropometric measurement),which could affect the prognosis of diseases, have been discussed. To this end, three-dimensionaltechnology is suggested as a reliable tool for various anthropometric data collectionand analysis in preventive medicine.
    Chang Gung medical journal 01/2011; 34(1).
Show more